Patent ID: 9562268
Date: 2017-02-07
CPC Classifications: C12Q,G01N

Claim:
1. A method of reducing the risk of a human patient for developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) induced by an anticonvulsant drug, the method comprising: identifying a human patient in need of treatment with an anticonvulsant drug; obtaining a genomic DNA sample from the peripheral blood of the patient; hybridizing to the genomic DNA sample an oligonucleotide that specifically hybridizes to the HLA-B*1502 allele; detecting the presence of the HLA-B*1502 allele in the genomic DNA sample, wherein the presence of the HLA-B*1502 allele in the sample indicates that the patient has an increased risk of developing SJS or TEN induced by carbamazepine or phenytoin; and; administering to the patient an anticonvulsant drug that is not carbamazepine or phenytoin.